Belsomra and Qvar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Belsomra (suvorexant) and Qvar (beclomethasone dipropionate). Common drug interactions include anxiety among females and pulmonary oedema among males.

The phase IV clinical study analyzes what interactions people have when they take Belsomra and Qvar. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Belsomra?

Belsomra has active ingredients of suvorexant. It is often used in insomnia. eHealthMe is studying from 12,961 Belsomra users. Check the latest studies of Belsomra.

What is Qvar?

Qvar has active ingredients of beclomethasone dipropionate. It is often used in asthma. eHealthMe is studying from 17,355 Qvar users. Check the latest studies of Qvar.



On Jul, 08, 2026

13 people who take Belsomra and Qvar together, and have interactions are studied.

Belsomra and Qvar drug interactions.

What are the common drug interactions of Belsomra and Qvar, by gender? *:

female:

  1. Anxiety
  2. Chronic kidney disease
  3. Dysphagia (a condition in which swallowing is difficult or painful)
  4. Flushing (the warm, red condition of human skin)
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Palpitations (feelings or sensations that your heart is pounding or racing)
  7. Pharyngeal oedema (abnormal accumulation of fluid in the cavities and intercellular spaces of the pharyngeal)
  8. Renal failure (kidney dysfunction)
  9. Abdominal pain
  10. Arthralgia (joint pain)

male:

  1. Pulmonary oedema (fluid accumulation in the lungs)
  2. Chronic kidney disease
  3. Depressed mood
  4. Depression
  5. Food craving
  6. Lethargy (tiredness)
  7. Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night)
  8. Renal tubular necrosis (death of kidney tubules)
  9. Somnolence (a state of near-sleep, a strong desire for sleep)
  10. Constipation

What are the common drug interactions of Belsomra and Qvar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Anxiety
  2. Chronic kidney disease
  3. Dysphagia (a condition in which swallowing is difficult or painful)
  4. Flushing (the warm, red condition of human skin)
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Palpitations (feelings or sensations that your heart is pounding or racing)
  7. Pharyngeal oedema (abnormal accumulation of fluid in the cavities and intercellular spaces of the pharyngeal)
  8. Renal failure (kidney dysfunction)
  9. Dyspnoea (difficult or laboured respiration)
  10. Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)

40-49:

n/a

50-59:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Arthralgia (joint pain)
  4. Cellulitis (infection under the skin)
  5. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  6. Drug ineffective
  7. Hypertension (high blood pressure)
  8. Injection site pain
  9. Macular degeneration (painless eye condition that leads to the gradual loss of central vision)
  10. Renal tubular necrosis (death of kidney tubules)

60+:

  1. Pulmonary oedema (fluid accumulation in the lungs)
  2. Constipation
  3. Food craving
  4. Lethargy (tiredness)
  5. Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night)
  6. Somnolence (a state of near-sleep, a strong desire for sleep)
  7. Platelet count decreased
  8. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  9. Supraventricular tachycardia (rapid heart rhythm originating at or above the atrioventricular node)
  10. Agitation (state of anxiety or nervous excitement)

What are the existing conditions these people have? *

  1. High Blood Pressure: 5 people, 38.46%
  2. Cough: 5 people, 38.46%
  3. Pain: 4 people, 30.77%
  4. Arrhythmias (irregular heartbeat): 3 people, 23.08%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 23.08%
  6. Hepatic Enzyme Increased: 3 people, 23.08%
  7. Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 23.08%
  8. Hypersensitivity: 3 people, 23.08%
  9. Oesophageal Carcinoma (cancer tumour of oesophagus): 3 people, 23.08%
  10. Neuropathy Peripheral (surface nerve damage): 3 people, 23.08%

* Approximation only. Some reports may have incomplete information.

Do you take Belsomra and Qvar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Belsomra and Qvar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Belsomra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Qvar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Belsomra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Qvar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on suvorexant and beclomethasone dipropionate (the active ingredients of Belsomra and Qvar, respectively), and Belsomra and Qvar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: